Browsing by Author "Tutuncu, Neslihan B."

Now showing 1 - 3 of 3

Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Region with Mild-to-Moderate Iodine Deficiency? A Prospective Study
(2018) Bozkus, Yusuf; Demir, Canan; Anil, Cuneyd; Mousa, Umut; Kut, Altug; Nar, Asli; Tutuncu, Neslihan B.; 0000-0002-6976-6659; 0000-0003-0998-8388; 0000-0002-8078-9376; 0000-0002-1816-3903; 0000-0003-3802-9733; 0000-0003-0776-8349; 29402848; AAA-5419-2021; AAA-2743-2021; I-1735-2018; AAK-4857-2021; ABG-5027-2020; A-2550-2015
Objective: The objective of this study was to assess the anti-proliferative pleiotropic effects of statins on thyroid function, volume, and nodularity. Subjects and Methods: One hundred and six hyperlipidemic patients were included in this prospective study. The 69 patients in the statin groups received atorvastatin (16 received 10 mg and 18 received 20 mg) or rosuvastatin (20 received 10 mg and 15 received 20 mg). The 37 patients in the control group, assessed as not requiring drugs, made only lifestyle changes. Upon admission and after 6 months, all patients were evaluated by ultrasonography as well as for lipid variables (total cholesterol, high-and low-density lipoprotein cholesterol, and triglycerides) and thyroid function and structure. Results: After 6 months, no differences in thyroid function, thyroid volume, the number of thyroid nodules, or nodule size were observed in the statin and control groups. In a subgroup analysis, total thyroid volume had decreased more in patients receiving 20 mg of rosuvastatin than that in the control group (p < 0.05). Maximum nodule size had decreased more in those receiving 10 mg of rosuvastatin (p < 0.05). Conclusions: Our results suggest an association between rosuvastatin treatment and smaller thyroid volume and maximum nodule diameter; this could be attributable to the antiproliferative effects of statin therapy on the thyroid. (C) 2018 The Author(s) Published by S. Karger AG, Basel
Low Prevalence of Periodontitis in Acromegaly: Growth Hormone May Exert a Protective Effect
(2015) Serinoz, Hulya; Ertorer, Melek Eda; Bascil, Sibel; Bakiner, Okan; Bozkirli, Emre; Tutuncu, Neslihan B.
Purpose: To evaluate bone mineral density (BMD) measurements and the presence of periodontitis in patients with acromegaly, as well as to inquire the impact of interfering factors. Material and Method: Forty-seven acromegalic patients with any accompanying condition known to affect calcium-bone metabolism and 60 age-matched healthy controls were included. Age, gender, duration and activity of acromegaly, past-present therapy options, pituitary hormone profiles, replacement therapies, and the results of periodontal analysis were recorded. Results: Eighteen patients were male (38.3%), 29 were female (61.7%). The mean age of the patients was 46.6 +/- 11.5 years, twenty-five (53.1%) had active, 22 (46.8%) had inactive acromegaly. The latter were older and had longer disease duration (p=0.04, p=0.003, respectively). Serum calcium and phosphorus levels, 24-hour urinary calcium excretion and BMD at the lumbar spine and femur neck insignificantly associated with disease activity (p>0.05). Osteoporosis was detected in 6 patients (12.76%). Periodontitis and advanced periodontitis were more common in control group (66.7% vs. 44.7%), (43.3% vs. 12.8%) (p=0.022, p=0.0001, respectively). There was no difference in chronic periodontitis and severity between active and inactive groups (48% vs. 40.9%; p=0.279). No difference was noted in other study parameters, as well. Repeated measures analysis of variance demonstrated statistically insignificant distribution between GH change in time and periodontitis subgroups. Discussion: We demonstrated that acromegaly exerted no clear negative impact on vertebral BMD in the absence of overt hypogonadism. Regardless of disease activity, acromegaly cases exhibited lower rates of periodontitis with less severity which remained unchanged in the presence of accompanying metabolic disorders known to have negative impact on periodontal tissue. Chronic exposure to excess GH may have a protective role against periodontitis.
Short-Term Effect of Hypergastrinemia Following Esomeprazole Treatment On Well-Controlled Type 2 Diabetes Mellitus: A Prospective Study
(2020) Bozkus, Yusuf; Mousa, Umut; Iyidir, Ozlem T.; Kirnap, Nazli; Demir, Canan C.; Nar, Asli; Tutuncu, Neslihan B.; 0000-0002-1816-3903; 0000-0002-6976-6659; 0000-0002-8078-9376; 0000-0001-5305-6807; 0000-0003-0998-8388; 31995024; ABG-5027-2020; AAA-5419-2021; AAK-4857-2021; I-1735-2018; K-7904-2019; AAA-2743-2021
Objective: Proton pump inhibitor (PPI) drugs reduce gastric acid secretion and lead to an increase in serum gastrin levels. Many preclinical and some clinical researches have established some positive effects of gastrin or PPI therapy on glucose regulation. The aim of this study was to prospectively investigate the short term effects of esomeprazole on glycaemic control in patients with type 2 diabetes mellitus. In addition, the presence of an association between this effect and gastrin levels was evaluated. Methods: Thirty-two subjects with type 2 diabetes mellitus were enrolled and grouped as intervention (n=16) and control (n=16). The participants in the intervention group were prescribed 40 mg of esomeprazole treatment for three months. At the beginning of the study and at the 3rd month, HbA1c level (%) and gastrin levels (pmol/L) of participants were assessed. Then, the groups were compared in terms of their baseline and 3rd month values. Results: In the intervention group, the mean gastrin level increased significantly from 34.3 +/- 14.4 pmol/L to 87.4 +/- 43.6 pmol/L (p<0.001). The mean HbA1c level was similar to the pre-treatment level (6.3 +/- 0.7% vs. 6.4 +/- 0.9%, p=0.441). There were no statistically significant differences in all parameters of the control group. The majority of individuals were on metformin monotherapy (65.6 %). The subgroup analysis of metformin monotherapy revealed that, in intervention group, there was a significant increase in gastrin levels (39.9 +/- 12.6 vs. 95.5 +/- 52.5, p=0.026), but the HbA1c levels did not change (6.0 +/- 0.4 % vs. 5.9 +/- 0.6 %, p=0.288); and in control group, gastrin levels did not change (37.5 +/- 26.7 vs. 36.1 +/- 23.3, p=0.367), but there was an increase in HbA1c levels (6.1 +/- 0.50 vs. 6.4 +/- 0.60, p=0.01). Conclusion: Our study demonstrates that esomeprazole has no extra benefit for the controlled diabetic patient in three months. However, in only the metformin-treated subgroup, esomeprazole may prevent the rise in HbA1c level.